Research Paper Volume 15, Issue 13 pp 6011—6030

Figure 2. BUB1 inhibition blocks EGFR signaling. MDA-MB-231-1833 (A) NCI-H358 (B) and MRC5 (C) cells were starved and pretreated with BUB1 kinase inhibitor 2OH-BNPP1 (10 μM) or EGFR inhibitor erlotinib (10 μM) for 1 hour followed by EGF (30 ng/mL) treatment for an additional 30 minutes. Resulting lysates were run on 4-12% Bis-Tris SDS-PAGE gels, transferred to PVDF membranes and probed with indicated antibodies. (D–F) western blots for phosphorylated proteins from (A–C) were quantitated (three separate biological repeats) using ImageJ and plotted.